Fosun Pharma (01061.HK): The biologics license application for HLX04-O, a biologic drug for the treatment of wet AMD using anti-VEGF eye injections, has been accepted.

Wisdom Financial News APP News, Yisheng Biotechnology (01061.HK) announced that the licensee (all are fully owned subsidiaries of the company) entered into a joint development license agreement with Shanghai Fuhong Hanlin Biotechnology Co., Ltd. (Fuhong Hanlin) to jointly develop licensed products according to the terms of the joint development license agreement and grant exclusive rights to the licensee for the licensed products. The licensed product is a biological drug containing recombinant anti-vascular endothelial growth factor humanized monoclonal antibody (anti-VEGF) as an active ingredient, intended for the treatment of exudative (wet) age-related macular degeneration (wet AMD).